Alpine Immune Sciences (ALPN) PT Set at $13.00 by Oppenheimer

Alpine Immune Sciences (NASDAQ:ALPN) has been assigned a $13.00 target price by research analysts at Oppenheimer in a research note issued on Monday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 170.83% from the company’s current price.

ALPN has been the subject of a number of other research reports. Piper Jaffray Companies began coverage on Alpine Immune Sciences in a research note on Thursday, September 27th. They set an “overweight” rating and a $12.00 price objective for the company. ValuEngine upgraded Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 23rd. Zacks Investment Research upgraded Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, November 27th. Finally, Raymond James began coverage on Alpine Immune Sciences in a research note on Monday, August 13th. They set a “buy” rating and a $13.00 price objective for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Alpine Immune Sciences currently has an average rating of “Buy” and an average price target of $12.67.

Shares of NASDAQ ALPN opened at $4.80 on Monday. Alpine Immune Sciences has a fifty-two week low of $4.51 and a fifty-two week high of $11.75. The company has a quick ratio of 9.20, a current ratio of 9.20 and a debt-to-equity ratio of 0.05. The company has a market cap of $66.46 million, a price-to-earnings ratio of -4.00 and a beta of 0.95.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.31). Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 43.25%. Equities analysts expect that Alpine Immune Sciences will post -2.62 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. DRW Securities LLC lifted its holdings in Alpine Immune Sciences by 138.7% during the 2nd quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock worth $184,000 after buying an additional 14,143 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Alpine Immune Sciences by 20.9% during the 2nd quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after buying an additional 21,124 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Alpine Immune Sciences by 122.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after buying an additional 18,052 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Alpine Immune Sciences by 5.2% during the 3rd quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares during the last quarter. 54.74% of the stock is currently owned by institutional investors.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

See Also: Investing strategies using the yield curve

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit